Acumen Pharmaceuticals In... (ABOS)
| Bid | 1.25 |
| Market Cap | 76.6M |
| Revenue (ttm) | 290K |
| Net Income (ttm) | -81.67M |
| EPS (ttm) | -1.38 |
| PE Ratio (ttm) | -0.92 |
| Forward PE | -1.05 |
| Analyst | Buy |
| Ask | 1.31 |
| Volume | 169,379 |
| Avg. Volume (20D) | 323,325 |
| Open | 1.25 |
| Previous Close | 1.26 |
| Day's Range | 1.23 - 1.30 |
| 52-Week Range | 1.24 - 5.09 |
| Beta | -0.01 |
About ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia....
Analyst Forecast
According to 3 analyst ratings, the average rating for ABOS stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 449.02% from the latest price.
3 months ago · seekingalpha.com
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call TranscriptAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q3 2024 Results Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Braun - Head of Investor Relations Dan O'Connell - Chief Executive Of...